C
Clearnotehealth
Bluestar Genomics Delivering Precision Epigenomic Medicine
About Clearnotehealth
Bluestar Genomics, now known as ClearNote Health, is a commercial-stage company that specializes in non-invasive cancer detection. The company operates in the healthcare and biotechnology market, with a primary focus on cancer research and diagnostics. They serve a broad client base that includes healthcare providers, cancer patients, and research institutions.
Read full description
Their business model revolves around the development and commercialization of innovative technologies for cancer detection. They use advanced research and development (R&D) methods to create solutions that prioritize patient needs. Their key offering is a non-invasive cancer detection method, which is a less painful and more convenient alternative to traditional cancer detection procedures.
The company also uses sophisticated data analytics to optimize user experience and improve their services. They collect and analyze data on user behavior and use this information to make improvements. This data-driven approach allows them to provide a more personalized and efficient service to their clients.
In terms of revenue, ClearNote Health likely generates income through the sale of their diagnostic services to healthcare providers and patients. They may also earn revenue from partnerships with other healthcare and research institutions, and possibly from referral commission fees.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- San Diego, United States
- Employees
- 57
- Open positions
- None listed
- Dealroom signal
- 55.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Clearnotehealth.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Jun 2026 | $52M | $350M | Mattias Westman · Stephen Quake | ↗ |
| SERIES COther financing | May 2021 | $70M | $280M | Mattias Westman · Pathology Asia Holdings | — |
Growth signals
Latest recorded traffic for Clearnotehealth is 5.9K monthly website visits. Clearnotehealth's team grew 14% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
Mattias Westman
Pathology Asia Holdings
Stephen Quake
Other known investors1 additional known investor
Stanford University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Clearnotehealth on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Clearnotehealth’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.